Drug intelligence / Profile preview

Androlen

Development stage: Unknown
Lead developer: QPharma
Modality: Small Molecules
Administration: Oral

Overview

Androlen is a multi-ingredient dietary supplement developed by Laboratorios Q Pharma, specifically formulated to support male reproductive health and fertility. It contains a synergistic blend of L-carnitine, acetyl-L-carnitine, L-arginine, glutathione, coenzyme Q10, zinc, folic acid, selenium, and vitamin B12. These components work together to improve sperm parameters, including concentration, motility, and morphology, by optimizing mitochondrial energy metabolism and providing antioxidant protection against oxidative stress. Androlen is typically used as a nutritional adjunct for men experiencing subfertility or those undergoing assisted reproductive techniques.

Brand names: Androlen
Other names: Androlen®

Targets

NOS1 (nNOS)CRAT (Carnitine O-acetyltransferase)

Beyond the preview

Go deeper on Androlen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Androlen.

Explore the full profile